STOCK TITAN

Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Aligos Therapeutics, Inc. (Nasdaq: ALGS) will present at the 2023 Piper Sandler Healthcare Conference in New York on November 30, 2023, at 12:30 p.m. ET. Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO, will be the presenter. The webcast link and replay details are available on the Aligos investor section of the website. The management team will also participate in investor 1x1 meetings during the conference.
Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, and the Aligos management team, will present at the 2023 Piper Sandler Healthcare Conference being held in New York on Thursday, November 30, 2023 at 12:30 p.m. ET.

Piper Sandler Healthcare Conference Information:

 Date Thursday, November 30, 2023  
 Time: 12:30 p.m. ET  
 Presenter: Lawrence Blatt, Ph.D., MBA, CEO of Aligos  
 Webcast: Link here  

A replay of the session will be available following the conference for 90-days through the Aligos investor section of the website https://investor.aligos.com/.

The Aligos management team will also participate in investor 1x1 meetings during the conference. Please contact your Piper Sandler representative to schedule one-on-one meetings with Aligos during the conference.

About Aligos

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of liver and viral diseases. Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver and viral diseases to discover and develop potentially best in class therapeutics for nonalcoholic steatohepatitis (NASH) and viruses with high unmet medical need such as coronaviruses and chronic hepatitis B (CHB).

Media Contact
Veronica Eames
LifeSci Communications
veames@lifescicomms.com

Investor Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com


The presentation will be on Thursday, November 30, 2023.

Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will be the presenter.

The webcast link and replay details will be available on the Aligos investor section of the website.

Yes, the management team will participate in investor 1x1 meetings during the conference. Contact your Piper Sandler representative to schedule meetings with Aligos.
Aligos Therapeutics Inc

NASDAQ:ALGS

ALGS Rankings

ALGS Latest News

ALGS Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Major

About ALGS

aligos therapeutics, inc., a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. its lead drug candidate is alg-010133, a synthetic oligonucleotide that is in phase i clinical trial for the treatment of chronic hepatitis b (chb). the company is also developing alg-000184, a capsid assembly modulator to treat chb; alg-020572, a oligonucleotide for the treatment of chb; alg-125097, an sirna drug candidate to treat chb; and alg-055009, a small molecule thr-㟠agonist for the treatment of non-alcoholic steatohepatitis. aligos therapeutics, inc. was founded in 2018 and is headquartered in south san francisco, california.